Arcus Biosciences, Inc., a biopharmacy company focused on oncology. (RCUS) We are trading 15% higher on Thursday. The company reported positive clinical activity from the 3-arm randomized Phase 2 ARC-7 trial on Wednesday.
According to the company, in the first interim analysis of a 3-group randomized phase 2 ARC-7 trial, both groups were domvanalimab-based combinations and were given as first-line treatment to people with metastatic non-small cells. If so, promising clinical activity was shown. lung cancer. Arcus Biosciences said all trials will continue as planned and data will be released at the end of the year.
The stock is currently trading at $ 27.00 and is up $ 3.65 or 15% on the New York Stock Exchange. RCUS has traded between $ 16.69 and $ 42.36 in the last 52 weeks.
Contact for comments and feedback: email@example.com
Arcus Biosciences up 15%
Source link Arcus Biosciences up 15%